IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Serum Interleukin-23 Associated with Disease Activitiy in Psoriatic Arthritis Patient

Author: AFIF ROMDLONI, LITA DIAH RAHMAWATI, JOEWONO SOEROSO
Abstract: Background: The pathogenesis of psoriatic arthritis has not yet been fully understood. Interleukin-23 (IL-23) dysregulation plays a dominant role in the development of chronic autoimmune inflammatory diseases including psoriatic arthritis. We aimed to examine the correlation between serum IL-23 and the parameters of psoriatic arthritis disease activity using DAPSA score. Methods: The cross sectional observational analytic study involved 32 research subjects of new psoriatic arthritis who were diagnosed based on CASPAR. Serum IL-23 levels were examined using the ELISA method with the ElabsienceR reagent. Disease activity using DAPSA scores was declared remission (score 0-4), mild (score >4-14), moderate (score >1-28), severe (score >28). Results: The subjects was 32 patients consisted 9 males and 23 females. The median age was 51 years, with range 17-60 years. The clinical presentation of symmetric polyartrhitis in 16 subjects (50%), asymmetric oligoarthritis in 13 subjects (13%), predominant DIP in 7 subjects (21.87%) and predominant spondyloarthritis (axial type) in 3 subjects (9.37%). The median DAPSA score was 21.6 (4.10-58.10). The median serum IL-23 level was 111.79 (27.54-3963) pg/mL. There was a significant positive correlation between serum IL-23 levels and DAPSA scores (p = 0.006, r = 0.472). Conclusion: Serum IL-23 levels associated with psoriatic arthritis disease activity using DAPSA score.
Keyword: Psoriatic arthritis, disease activity, IL-23
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free